MA40074A - Composés liant ras multivalents - Google Patents

Composés liant ras multivalents

Info

Publication number
MA40074A
MA40074A MA040074A MA40074A MA40074A MA 40074 A MA40074 A MA 40074A MA 040074 A MA040074 A MA 040074A MA 40074 A MA40074 A MA 40074A MA 40074 A MA40074 A MA 40074A
Authority
MA
Morocco
Prior art keywords
methods
compounds
multivalent
binding compounds
compositions
Prior art date
Application number
MA040074A
Other languages
English (en)
Inventor
Brent R Stockwell
Matthew Welsch
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA40074A publication Critical patent/MA40074A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, entre autres, des composés qui lient sélectivement une protéine ras en deux sites ou davantage et des procédés pour leur synthèse. L'invention concerne également des compositions et des kits contenant les composés, ainsi que des procédés d'utilisation des composés et des compositions pour améliorer ou traiter les effets d'une maladie associée à une signalisation ras modifiée, comme un cancer, chez un sujet et des procédés pour provoquer la mort des cellules cancéreuses. L'invention concerne également des procédés d'identification d'un composé multivalent qui se lie sélectivement à une protéine cible.
MA040074A 2014-05-30 2015-05-29 Composés liant ras multivalents MA40074A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462005831P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
MA40074A true MA40074A (fr) 2015-12-03

Family

ID=54700076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040074A MA40074A (fr) 2014-05-30 2015-05-29 Composés liant ras multivalents

Country Status (5)

Country Link
US (1) US9926293B2 (fr)
EP (1) EP3148981A4 (fr)
CA (1) CA2950581A1 (fr)
MA (1) MA40074A (fr)
WO (1) WO2015184349A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (fr) 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
EP3283462B1 (fr) 2015-04-15 2020-12-02 Araxes Pharma LLC Inhibiteurs tricycliques condensés de kras et procédés pour les utiliser
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356351A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356349A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines mutantes kras g12c
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356354A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
WO2017070256A2 (fr) 2015-10-19 2017-04-27 Araxes Pharma Llc Méthode de criblage d'inhibiteurs de ras
EP3377481A1 (fr) 2015-11-16 2018-09-26 Araxes Pharma LLC Composés quinazoline substitués en position 2 comprenant un groupe hétérocyclique substitué et leur méthode d'utilisation
WO2017100546A1 (fr) 2015-12-09 2017-06-15 Araxes Pharma Llc Procédés de préparation de dérivés de quinazoléine
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN109843856B (zh) 2016-05-18 2023-05-02 米拉蒂治疗股份有限公司 Kras g12c抑制剂
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (fr) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibiteurs de protéines mutantes kras g12c
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US11104955B2 (en) 2016-12-30 2021-08-31 Children's Medical Center Corporation MAP2K1 (MEK1) as a therapeutic target for arteriovenous malformations and associated disorders
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140513A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573954A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
KR102861303B1 (ko) 2017-11-15 2025-09-17 미라티 테라퓨틱스, 인크. Ｋｒａｓ ｇ12ｃ 억제제
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP3806841A1 (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Diminution de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaire
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
WO2020055761A1 (fr) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Polythérapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
CA3112129A1 (fr) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Polytherapies
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
CA3148745A1 (fr) 2019-08-29 2021-03-04 Xiaolun Wang Inhibiteurs de kras g12d
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
WO2021222138A1 (fr) * 2020-04-27 2021-11-04 Development Center For Biotechnology Composés pour la dégradation de la protéine ras mutante
US12286431B2 (en) 2020-09-11 2025-04-29 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
EP4262803A4 (fr) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Inhibiteurs pan-kras de tétrahydropyridopyrimidine
WO2023150639A2 (fr) * 2022-02-04 2023-08-10 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs à petites molécules d'enzymes gtpase et leurs utilisations
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2025148858A1 (fr) * 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 Inhibiteur de fak et inhibiteur pan-ras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169788B2 (en) * 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
CN101360422B (zh) * 2005-11-23 2013-10-23 得克萨斯大学体系董事会 致癌Ras特异性细胞毒化合物及其使用方法
WO2013026064A1 (fr) * 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Dispositifs mucoadhésifs anti-abus destinés à administrer de la buprénorphine
CN104379563B (zh) * 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP2671575A1 (fr) * 2012-06-04 2013-12-11 Universität Regensburg Inhibiteurs de RAS
WO2015074123A1 (fr) * 2013-11-25 2015-05-28 Novogen ltd Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux
US20170158702A1 (en) * 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds

Also Published As

Publication number Publication date
WO2015184349A3 (fr) 2016-01-21
EP3148981A4 (fr) 2017-11-08
CA2950581A1 (fr) 2015-12-03
WO2015184349A2 (fr) 2015-12-03
US9926293B2 (en) 2018-03-27
US20160229836A1 (en) 2016-08-11
EP3148981A2 (fr) 2017-04-05

Similar Documents

Publication Publication Date Title
WO2015184349A3 (fr) Composés liant ras multivalents
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
NZ754051A (en) Novel antibodies and uses thereof
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
MY184895A (en) Antibody constructs for dll3 and cd3
EA201891366A1 (ru) Гуманизированные антитела против cd73
PH12018500216B1 (en) Antibody constructs for cd70 and cd3
NZ738979A (en) Pd-1 antibodies
MX2016009877A (es) Anticuerpos anti-baff novedosos.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
MX386342B (es) Móleculas de unión a her2 y cd3 biespecíficas.
WO2017035430A3 (fr) Anticorps anti-alk et leurs procédés d'utilisation
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA201890315A1 (ru) Молекулы антител, связывающие cd22
WO2019089753A3 (fr) Anticorps cd137 et antagonistes pd-1 et leurs utilisations
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.